playcrashbandicootonline| Pacific Securities: Generic drugs are expected to open the ceiling for growth

News summary

[Pacific Securities: Generic drugs are expected to open the growth ceiling] Securities Times News, Pacific Securities Research News pointed out that according to the 2023 annual report and the 2024 quarterly report, it has been disclosedplaycrashbandicootonlineAs a result, divisions have emerged within the generic drug sector, and the performance of some companies has reached an inflection point. With the gradual impact of centralized procurementplaycrashbandicootonline.playcrashbandicootonline..

Newsletter text

[Pacific Securities: Generic drugs are expected to open the growth ceiling] Securities Times News, Pacific Securities Research News pointed out that according to the 2023 annual report and the 2024 quarterly report, it has been disclosedplaycrashbandicootonlineAs a result, divisions have emerged within the generic drug sector, and the performance of some companies has reached an inflection point. As the impact of centralized procurement is gradually cleared out, the stable profits of generic drug companies provide a good margin of safety for the company's valuation. Superimposed innovation transformation is expected to usher in a reshaping of valuation, and going out to sea is expected to open up the growth ceiling. Suggest attention to: 1) Companies with mature and complete products and academic promotion, strong project establishment capabilities, and good certainty in future performance, such as Fuyuan Pharmaceutical;2) Companies with innovative drug pipelines entering the redemption stage and high flexibility in valuation repair, such as Jingxin Pharmaceutical, Yifan Pharmaceutical, etc. Proofread: Peng Qihua